FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379982010> ?p ?o ?g. }

• W4379982010 endingPage "69" @default.
• W4379982010 startingPage "69" @default.
• W4379982010 abstract "Introduction: Outcomes for high-risk pediatric and adolescent and young adult (AYA) classic Hodgkin lymphoma (cHL) improved substantially with the addition of brentuximab vedotin (Bv) to AVEPC (adriamycin, vincristine, etoposide, prednisone, cyclophosphamide) chemotherapy. As patients with stage IV disease have poor outcomes, we evaluated the prognostic implications of sites contributing to stage IV disease. Methods: On AHOD1331 (NCT02166463), patients age 2–21 years with high-risk cHL (stage IIB with bulk, IIIB, IVA, and IVB) were randomized to 5 cycles of AB (bleomycin)VE-PC versus Bv-AVE-PC, and consolidative radiotherapy based on interim response and large mediastinal adenopathy at diagnosis. Patients with stage IV disease, as determined by protocol defined and centrally reviewed PET-CT, were identified. Stage IV was defined as disseminated involvement of ≥1 extralymphatic organ or tissues (with or without lymph node involvement) or isolated extralymphatic organ involvement with distant nodal involvement. E-lesions were distinguished from sites of stage IV involvement in the lung, but any liver and/or bone marrow involvement, regardless of contiguity, was considered stage IV. Central review was performed to confirm institutional classification of stage, upstaging 33 patients to stage IV and downstaging 17 among the 353 enrolled and stratified as Stage IV by the institution. Baseline characteristics and progression-free survival (PFS) were compared by pattern of metastatic involvement (lung only, bone only, bone marrow only, or multi-site, defined as >1 site of involvement). Results: 369 patients (median age 15 years, range 3–22) with stage IV disease treated on AHOD1331 were included, of which 183 (50%) were treated with ABVE-PC and 186 (50%) with Bv-AVE-PC. Patterns of disease included: isolated involvement of lung (185; 50%); bone marrow (5; 1%); or bone (8; 2%), and 171 (46%) had multi-site involvement. B symptoms were present in 80% and 88% with bone marrow or bone involvement respectively, 50% of those with lung, and 57% with multi-site disease. The 3 year-PFS (95% CI) by site of involvement was: 88.0% (82.3, 91.9) for lung, 100% for isolated bone marrow or bone, and 82.5% (75.8, 87.5) for multi-site (p = 0.21). Bv-AVE-PC significantly improved PFS among stage IV patients compared to ABVE-PC (3-year PFS 90.2% vs. 81.5%, p = 0.01). Among those with isolated lung involvement, there was a non-significant increased PFS with Bv (3-year PFS 91.2% vs. 84.7%, p = 0.16), while those with multi-site metastatic disease experienced significantly improved PFS with Bv (3 year-PFS 88.1% vs. 77.1%, p = 0.05). Conclusions: Among pediatric and AYA patients with stage IV cHL, PFS was notably improved with Bv among patients with multi-site metastatic involvement. These results will help guide future efforts to understand strategies to improve outcomes among children with stage IV disease. The research was funded by: Supported in part by grants from the National Institutes of Health (U10CA098543, U10CA180899, and U10CA180886; all to the Children’s Oncology Group), the Quality Assurance Review Center (U10CA29511), Imaging and Radiology Oncology Core Rhode Island (U24CA180803), and St. Baldrick’s Foundation (to the Children’s Oncology Group) Keywords: Hodgkin lymphoma, molecular targeted therapies, Lymphoid Cancers - Other No conflicts of interests pertinent to the abstract." @default.
• W4379982010 created "2023-06-10" @default.
• W4379982010 creator A5006768334 @default.
• W4379982010 creator A5036356438 @default.
• W4379982010 creator A5043898160 @default.
• W4379982010 creator A5054697421 @default.
• W4379982010 creator A5061910742 @default.
• W4379982010 creator A5065571990 @default.
• W4379982010 creator A5068734036 @default.
• W4379982010 creator A5070800902 @default.
• W4379982010 creator A5078705257 @default.
• W4379982010 creator A5089358491 @default.
• W4379982010 creator A5091294211 @default.
• W4379982010 date "2023-06-01" @default.
• W4379982010 modified "2023-10-12" @default.
• W4379982010 title "PATTERNS OF PRESENTATION AND OUTCOMES IN STAGE IV HODGKIN LYMPHOMA: A REPORT FROM THE CHILDREN’S ONCOLOGY GROUP (COG) AHOD1331 TRIAL" @default.
• W4379982010 doi "https://doi.org/10.1002/hon.3163_34" @default.
• W4379982010 hasPublicationYear "2023" @default.
• W4379982010 type Work @default.
• W4379982010 citedByCount "0" @default.
• W4379982010 crossrefType "journal-article" @default.
• W4379982010 hasAuthorship W4379982010A5006768334 @default.
• W4379982010 hasAuthorship W4379982010A5036356438 @default.
• W4379982010 hasAuthorship W4379982010A5043898160 @default.
• W4379982010 hasAuthorship W4379982010A5054697421 @default.
• W4379982010 hasAuthorship W4379982010A5061910742 @default.
• W4379982010 hasAuthorship W4379982010A5065571990 @default.
• W4379982010 hasAuthorship W4379982010A5068734036 @default.
• W4379982010 hasAuthorship W4379982010A5070800902 @default.
• W4379982010 hasAuthorship W4379982010A5078705257 @default.
• W4379982010 hasAuthorship W4379982010A5089358491 @default.
• W4379982010 hasAuthorship W4379982010A5091294211 @default.
• W4379982010 hasBestOaLocation W43799820101 @default.
• W4379982010 hasConcept C126322002 @default.
• W4379982010 hasConcept C141071460 @default.
• W4379982010 hasConcept C143998085 @default.
• W4379982010 hasConcept C146357865 @default.
• W4379982010 hasConcept C151730666 @default.
• W4379982010 hasConcept C207103383 @default.
• W4379982010 hasConcept C2776305933 @default.
• W4379982010 hasConcept C2776694085 @default.
• W4379982010 hasConcept C2776755627 @default.
• W4379982010 hasConcept C2777132456 @default.
• W4379982010 hasConcept C2778119113 @default.
• W4379982010 hasConcept C2779338263 @default.
• W4379982010 hasConcept C2779429289 @default.
• W4379982010 hasConcept C2779714933 @default.
• W4379982010 hasConcept C44249647 @default.
• W4379982010 hasConcept C71924100 @default.
• W4379982010 hasConcept C86803240 @default.
• W4379982010 hasConceptScore W4379982010C126322002 @default.
• W4379982010 hasConceptScore W4379982010C141071460 @default.
• W4379982010 hasConceptScore W4379982010C143998085 @default.
• W4379982010 hasConceptScore W4379982010C146357865 @default.
• W4379982010 hasConceptScore W4379982010C151730666 @default.
• W4379982010 hasConceptScore W4379982010C207103383 @default.
• W4379982010 hasConceptScore W4379982010C2776305933 @default.
• W4379982010 hasConceptScore W4379982010C2776694085 @default.
• W4379982010 hasConceptScore W4379982010C2776755627 @default.
• W4379982010 hasConceptScore W4379982010C2777132456 @default.
• W4379982010 hasConceptScore W4379982010C2778119113 @default.
• W4379982010 hasConceptScore W4379982010C2779338263 @default.
• W4379982010 hasConceptScore W4379982010C2779429289 @default.
• W4379982010 hasConceptScore W4379982010C2779714933 @default.
• W4379982010 hasConceptScore W4379982010C44249647 @default.
• W4379982010 hasConceptScore W4379982010C71924100 @default.
• W4379982010 hasConceptScore W4379982010C86803240 @default.
• W4379982010 hasIssue "S2" @default.
• W4379982010 hasLocation W43799820101 @default.
• W4379982010 hasOpenAccess W4379982010 @default.
• W4379982010 hasPrimaryLocation W43799820101 @default.
• W4379982010 hasRelatedWork W1977168953 @default.
• W4379982010 hasRelatedWork W1994837348 @default.
• W4379982010 hasRelatedWork W2068354603 @default.
• W4379982010 hasRelatedWork W2088539798 @default.
• W4379982010 hasRelatedWork W2162714191 @default.
• W4379982010 hasRelatedWork W2335762340 @default.
• W4379982010 hasRelatedWork W2399446920 @default.
• W4379982010 hasRelatedWork W2887013637 @default.
• W4379982010 hasRelatedWork W2970608623 @default.
• W4379982010 hasRelatedWork W4290257576 @default.
• W4379982010 hasVolume "41" @default.
• W4379982010 isParatext "false" @default.
• W4379982010 isRetracted "false" @default.
• W4379982010 workType "article" @default.